A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
Wang D, Wang J, Hu G, Wang W, Xiao Y, Cai H, Jiang L, Meng L, Yang Y, Zhou X, Hong Z, Yao Z, Xiao M, Chen L, Mao X, Zhu L, Wang J, Qiu L, Li C, Zhou J.
Wang D, et al. Among authors: wang w, wang j.
Blood. 2021 May 27;137(21):2890-2901. doi: 10.1182/blood.2020008936.
Blood. 2021.
PMID: 33512480
Free article.
Clinical Trial.